Multikinase inhibitors use in differentiated thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Thyroid cancer is the most common endocrine malignancy with increasing incidence.
• Localized differentiated thyroid cancer (DTC) typically involves surgery, radioactive iodine, and hormone replacement.
• Systemic therapy is needed for a minority of patients with metastatic DTC, as cytotoxic chemotherapy is often ineffective.

Purpose of the Study:

• To review newly developed small-molecule tyrosine kinase inhibitors (TKIs) for advanced thyroid cancer management.
• To discuss the evolving role of TKIs as molecular targeted therapy based on pathway understanding.
• To highlight the mechanisms of action and challenges associated with TKI use in DTC.

Main Methods:

• Review of current literature on small-molecule tyrosine kinase inhibitors (TKIs).
• Focus on molecular targeted therapies for advanced and metastatic differentiated thyroid cancer (DTC).
• Analysis of signaling pathways targeted by TKIs, including VEGFR, BRAF, MAPK/ERK, and mTOR.

Main Results:

• TKIs represent a novel approach for advanced/metastatic DTC, outperforming traditional chemotherapy.
• Targeting vascular endothelial growth factor receptor (VEGFR) signaling is a primary TKI strategy for disrupting tumor vascular supply.
• Other TKI targets include BRAF, MAPK/ERK kinase, and mammalian target of rapamycin (mTOR) pathways.
• TKIs demonstrate superior efficacy but are associated with significant adverse effects requiring management.

Conclusions:

• Tyrosine kinase inhibitors (TKIs) are increasingly important in treating advanced differentiated thyroid cancer (DTC).
• Understanding molecular pathways allows for targeted TKI therapy, improving outcomes beyond cytotoxic agents.
• Effective management of TKI-related adverse effects is crucial for patient treatment continuation and success.